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Summary: Mitochondrial myopathies and defects in oxidative phosphory- 
lation have been described in some patients with peroxisomal disorders. Although 
peroxisomes and mitochondria play a role in the r-oxidation of fatty acids, the 
metabolic interactions between the two are not well defined. Defects in 
peroxisomal r-oxidation are associated with extracellular accumulation of very 
long-chain fatty acids and may be accompanied by alterations in the intracellular 
pool of fatty acyl-CoAs, which are known to alter mitochondrial function. This 
study was initiated to examine alterations in the intracellular pool of acyl-CoAs 
and mitochondrial function in two children with generalized disorders of 
peroxisomal function and clinical lactic/pyruvic acidaemia. Fibroblasts were 
cultured from skin biopsies obtained from one child with neonatal adrenoleuko- 
dystrophy (NALD) and another with rhizomelic chondrodysplasia punctata 
(RCDP). Fibroblast lactate oxidation was significantly inhibited in NALD by 
76% and RCDP by 92% compared to control values of 1.9 +_ 0.1nmol/min 
per mg protein. Pyruvate dehydrogenase (PDH) (mean +_ SEM; activity nmol/ 
min per mg protein) was: NALD 0.55 _+ 0.02 (p < 0.01), RCDP 0.44 __ 0.02 
(p < 0.01), and controls 0.83 _+ 0.02. The acid-insoluble (long-chain and very 
long-chain) acyl-CoA levels (mean _+ SEM; pmol/mg protein) were: NALD 
129 _+ 69 (p < 0.01), RCDP 65 + 15 (p < 0.05), and control 45 _+ 7. These two 
patients with generalized peroxisomal disorders exhibited an increase in 
intracellular acyl-CoA species accompanied by decreased PDH activity and 
clinical lactic/pyruvic acidaemia. 
Isolation and biochemical characterization of peroxisomes began less than thirty 
years ago. Peroxisomes have multiple biosynthetic functions and, like mitochondria, 
play a role in the r-oxidation of fatty acids (Wanders et al 1990). The main function 
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of the peroxisomal oxidation system is the/?-oxidation of very long-chain fatty acids 
(VLCFA), prostaglandins, dicarboxylic acids, xenobiotic fatty acids and hydroxylated 
5-/?-cholestanoic acids (Schulz 1991). The products of peroxisomal/?-oxidation, chain- 
shortened acyl-CoAs, enter the mitochondrial /?-oxidation pathway, promoting 
oxidative phosphorylation and supplying acetyl-CoA for ketogenesis. 
The metabolic interaction between peroxisomes and mitochondria is not well 
defined. Goldfischer (1973) observed hyperlactataemia in two patients with peroxi- 
somal disorders. In addition, abnormalities in the mitochondrial electron-transport 
chain in Zellweger syndrome have been described (Kelley and Corkey 1983; Trijbels 
et al 1983; Roels et al 1988), and patients with peroxisomal disorders have been 
reported to develop mitochondrial myopathies (Sarnat et al 1983; Wolff et al 1986). 
Abnormal oxidative phosphorylation has also been described in an infant with 
Zellweger syndrome (Muller-Hocker et al 1984). 
Defects in peroxisomal /?-oxidation are accompanied by an increase in the 
extracellular pool of fatty acids as indicated by increased plasma concentrations of 
VLCFA. It is not known whether there is a concurrent increase in the intracellular 
pool of acyl-CoAs that could affect mitochondrial function. Acyl-CoA molecules 
appear to have regulatory effects on a variety of reactions and have been shown to 
inhibit ureagenesis, gluconeogenesis and mitochondrial energy metabolism (Corkey 
and Deeney 1990). Long-chain acyl-CoAs have also been shown to inhibit the activity 
of pyruvate dehydrogenase complex, an enzyme composed of pyruvate dehydrogenase 
(El; EC 1.2.4.1), dihydrolipoyl transacetylase (E2; EC 2.3.1.12) and dihydrolipoyl 
dehydrogenase (E3; EC 1.6.4.3) (Kiechle et al 1990b; Moore et al 1992). This study 
examines alterations in the intracellular pool of acyl-CoAs in cultured skin fibroblasts 
from two patients with peroxisomal disorders and their relation to mitochondrial 
metabolism. 
METHODS 
Patient 1: N.R. was born on 26 May 1983 following a full-term gestation. Birth 
weight was 3.13 kg (50th percentile), length 54cm (95th percentile) and head circum- 
ference 34.5 cm (50th percentile). He was evaluated at 7 weeks of age because of failure to 
thrive and was noted to have hypotonia and enlarged anterior and posterior font- 
anelles with diastasis of the sagittal suture. Serum electrolytes were: sodium = 
145mmol/L (139-146), potassium=6.5mmol/L (4.0-6.2), chloride= l l l  mmol/L 
(96-106) and bicarbonate = 19 mmol/L (24-30). Serum lactic acid and pyruvic acid were 
elevated (Table 1). Hepatomegaly was present at age 4 months and serum amino- 
transferase levels were elevated (Table 1). Percutaneous liver biopsy showed abnormal 
lobular architecture with fibrous septa extending from portal tracts into the surround- 
ing parenchyma. By 8 months of age he could not visually fix on objects and had 
wandering nystagmus. Ophthalmological evaluation revealed bilateral punctate 
cortical and plaque-like nuclear changes, optic atrophy and retinal degeneration. 
A skin biopsy was performed at 1 year of age and fibroblasts were cultured, 
harvested and assayed for the activity of the peroxisomal membrane enzyme, 
dihydroxyacetone phosphate acyltransferase (DHAP-AT) (Datta et al 1984). The 
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Table 1 Results of clinical laboratory tests 
Holmes  et al. 
Test Reference range N A L D  R C D P  
Serum AST (U/L) 20-45 97 44 
Serum ALT (U/L) 3-20 39 14 
Plasma very long-chain fatty acids 
C26 (gg/ml) 0,33 + 0.18 1.49 0.36 
C26/C22 0,01 ___+ 0.01 0.22 0.02 
Plasma phytanate (~tmol/L) < 9.6 9.8 12.2 
Plasma carnitines 
Free (/1tool/L) 35 55 9 42 
Total (#mol/L) 45-65 17 50 
Urine acylcarnitine profile N a N N 
Urine organic acids ND b Adipic, suberic ND 
Serum lactate (retool/L) 0.6-1.8 2.8 2.1 
Serum pyruvate (#tool/L) 30-70 200 130 
NALD = neonatal adenoleukodystrophy; RCDP = rhizomelic chondrodysplasia punctata 
aN = within the reference range determined by mass spectrometry at Duke University Medical Center, 
Pediatric Metabolism Laboratory 
bND = none detectable 
activity was 30% of control (Wilson et al 1986). Levels of C26 VLCFA and the ratio 
of C26/C22 assayed at 20 months of age were elevated (Table 1). The phospholipid 
composition of erythrocytes was measured when the child was 2.5 years old. The 
erythrocyte phosphoethanolamine plasmalogen levels were 4% as compared to 
reference values of 12% (Wilson et al 1986) (Table 1). These results confirm the 
diagnosis of neonatal adrenoleukodystrophy (NALD; McKusick 20237). 
The child is currently enrolled in special education classes with a level of 
development equivalent to a young toddler. He has not yet developed clinical or 
laboratory evidence of adrenal insufficiency (normal Cortrosyn stimulation test at 
age 8.5 years). 
Pat ien t  2." G.B. was born on 29 November  1989 by Caesarean section because of 
failure to progress and fetal distress. Gestational age was determined by physical 
examination at 33 weeks, birth weight 2.13 kg (<  5th percentile) and length 43 cm 
(<  5th percentile). She had limb disproportion and radiographs showed rhizomelic 
shortening of the extremities, metaphyseal splaying, and punctate epiphyseal stippling 
diagnostic of rhizomelic chondrodysplasia punctata (RCDP; McKusick 21510). 
Bilateral nuclear cataracts were present. 
At 1 month of age a sample of blood was sent to the Kennedy Institute for 
Handicapped Children (Baltimore, Maryland, USA) for analysis of erythrocyte 
plasmalogens and plasma VLCFA. Red blood cell plasmalogen levels were measured 
as dimethylacetal (DMA) and the ratio of D M A  to the respective chain-length fatty 
acid was calculated. The mean value of C t6-DMA/C16 fatty acid was 0.002 (reference 
range 0.065 +_ 0.010) and C18-DMCA/Cls  fatty acid was 0.003 (reference range 
0.195 + 0.035). The ratio C26/C22 VLCFA was only slightly higher than normal 
(Table 1). A second sample was obtained at age 20 months and assayed for phytanic 
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acid (Table 1). The depressed red blood cell plasmalogens, near normal levels of 
VLCFA and mildly elevated phytanic acid are consistent with the diagnosis of RCDP. 
The infant underwent cataract surgery at 2 months of age and has been wearing 
corrective lenses. Serum electrolytes have been normal; however, serum lactic acid 
and pyruvic acid were found to be elevated at age 31 months (Table 1). Growth and 
development are delayed and she currently attends an early intervention school where 
she receives occupational and physical therapy. 
FibrobIasts." Skin biopsies were performed on these two patients after obtaining 
informed consent from the parents and following guidelines established by the William 
Beaumont Hospital Human Investigation Committee. Biopsy specimens obtained 
from remnants of human foreskin removed from healthy infants undergoing routine 
circumcision and from adult volunteers were used as controls. Skin biopsy specimens 
were subcultured in Eagle's Minimum Essential Medium (MEM) (Mediatech, 
Washington, DC, USA) supplemented with 15% fetal bovine serum (Biocell, Carson, 
CA, USA), 100 U/ml penicillin G potassium, 100 pg/ml streptomycin sulphate (Gibco, 
Grand Island, NY, USA) and 100#U/ml insulin (Sigma, St Louis, MO, USA). 
Fibroblasts were grown as monolayer cultures and maintained in a 37°C humidified 
incubator containing a mixture of 95% air and 5% CO2. Medium was replaced twice 
a week and cells passed during their log growth phase. Cultures were routinely 
screened for mycoplasma contamination by Mycotrim TC (Hanna Biologicals Inc., 
Alameda, CA, USA). 
Lactate oxidation." An assay was developed to screen for mitochondrial metabolic 
dysfunction by measuring oxidation of lactate by fibroblasts. Metabolism of D, L-[I- 
14C]lactate was measured in fibroblast monolayers grown to confluence in 25-cm 2 
tissue flasks containing MEM. Fibroblasts were washed twice with phosphate- 
buffered saline then treated with phosphate-buffered saline containing 25 ~tmol/L 
L-lactate (Sigma) and 0.1 ~tCi/ml D,L-[1-14C]lactate (American Radiochemical Co., St. 
Louis, MO, USA) and slowly shaken at 37°C for 2 h 40 min. Filter paper moistened 
with 0.2ml of 100g/L sodium hydroxide, used to collect atmospheric 1'~CO2, was 
suspended in the flask with an airtight stopper directly above the fibroblast monolayer. 
Each filter was transferred into scintillation vials and the amount of 14CO 2 liberated 
was determined. The cells were then harvested for protein determination. Activity 
was expressed as nmol 14CO 2 released per rain per mg cellular protein. Background 
activity determined using flasks with no cells and containing only 0.1/~Ci D,L-[1- 
14C]lactate in 1 ml phosphate-buffered saline was subtracted from both the control 
and patient results. 
Pyruvate dehydrogenase (PDH)." Fibroblasts were harvested 3-4 days after reaching 
confluence. Two 150-cm 2 tissue flasks, containing approximately 3.0 × 107 cells, were 
washed three times with calcium-free and magnesium-free phosphate-buffered saline 
(pH 7.4). After the final wash, 2ml homogenization buffer containing 25mmol/L 
sodium fluoride, 4mmol/L dichloracetic acid, l mmol/L dithiothreitol and 
0.25 mmol/L sucrose in 40 mmol/L phosphate-buffered saline (pH 7.4) was added to 
J. lnher. Metab. Dis. 16 (1993) 
372 Holmes et al. 
the monolayers. The cells were transferred into 5-ml cryogenic vials. The sample was 
homogenized using a glass Potter-Elvehjem homogenizer at setting 6 for 6 seconds. 
The cell homogenate was further frozen and thawed three times in a dry-ice-acetone 
bath and centrifuged for 15 min at 35 000g in a refrigerated Beckmann J2-21 centrifuge. 
The supernatants were maintained on ice and assayed immediately for PDH activity 
and total protein determination (Smith et al 1985). The phosphorylation state of the 
PDH complex was stabilized by treatment of the fibroblasts with dichloracetic acid 
to inhibit PDH kinase (EC 2.7.1.99) (Whitehouse et al 1974) and sodium fluoride to 
inhibit the PDH phosphatase (EC 3.1.3.43) (Hucho et al 1972). 
A radiochemical method based on the specific decarboxylation of [1-14C]pyruvate 
to 14CO 2 has been employed in the measurement of PDH activity. However, [1- 
14C]pyruvate is unstable and undergoes spontaneous non-enzymatic decarboxylation 
that may reduce the sensitivity of the assay (Williams et al 1978; Constantopoulos 
and Barranger 1984; Kiechle et al 1990a). An assay was developed by Schofield et al 
(1980) to overcome these problems using in situ generation of [1-z4C]pyruvate from 
[1-14C]lactate and is modified as described by Buffington et al (1984), who added 
two phosphorylation/dephosphorylation inhibitors of PDH complex, NaF and DCA, 
to measure PDH activity at the time of homogenization. 
The assay mixture containing 50mmol/L potassium phosphate buffer (pH 7.4), 
2.5mmol/L MgC12, 1.5mmol/L fl-nicotinamide-adenine dinucleotide, 500#mol/L 
CaC12, 80/~mol/L thiamine pyrophosphate, 100 mU/ml phosphotransacetylase, 
0.2 mmol/L coenzyme A (CoASH), 1 mmol/L dithiothreitol and the fibroblast suspen- 
sion (20-100#1) containing 0.05-0.25mg protein was preincubated for 10min at 
37°C. The reaction was started by adding 10 IU L-lactate dehydrogenase, 1.1 mmol/L 
L-lactate and 0.1 #Ci/ml D,L-[1-~4C]lactate to the assay mixture for a total volume 
of 0.5 ml. Filter paper moistened with 0.2 ml of 100 g/L sodium hydroxide, used for 
trapping ~4CO2, was then suspended in a vial with an airtight stopper directly over 
the assay mixture. This linear reaction (Hansen 1982) was stopped after 60min at 
37°C by addition of 3 mol/L H2SO 4. Incubation continued for 30min at 37°C and 
the filter paper was transferred to a vial containing scintillation fluid for the 
determination of ~4C02 liberated. 
Experiments were performed in triplicate. 'Blank' values were obtained from 
identical assay tubes without CoASH and fl-nicotinamide-adenine dinucleotide. PDH 
activity is expressed as nmol ~4CO2 released per min per mg of homogenate protein. 
Values are expressed as the mean + SEM. 
Citrate synthase and catalase: For the determination of citrate synthase (EC 4.1.3.7), 
catalase (EC 1.11.1.6), acyl-CoA synthetase (C4 to Cll, EC 6.2.1.2; C 6 to C2o, EC 
6.2.1.3), acyl-CoA hydrolase, and acyl-CoA levels, the fibroblasts were prepared in 
the same manner. Frozen packed cells were dispersed in 3 volumes of ice-cold 
0.25 mol/L sucrose-0.01 mmol/L potassium phosphate buffer (pH 7.4) and homogen- 
ized for 40 s with a Tissue-Tearer at the lowest setting. Aliquots of h0mogenate 
were used for protein assay, enzyme assay, and CoA determinations. Standard 
spectrophotometric assays were employed for assay of citrate synthase (EC 4.1.3.7) 
(Shepherd et al 1969) and catalase (EC 1.11.1.6) (Johansson and Hakan Borg 1988). 
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Acyl-CoA synthetase: Incubation mixture (0.25ml) containing 100mmol/L Tris- 
HC1 buffer (pH 8.0), 150mmol/L KC1, 15mmol/L MgC12, lmmol/L CoASH, 
10mmol/L adenosine triphosphate and l mmol/L [1-14C]palmitate-0.2mmol/L 
albumin was added to tubes containing 0.12mg of fibroblast homogenate. The 
reaction proceeded in a linear manner for 20min at 37°C and was terminated by 
addition of 0.5 ml Dole reagent (Hosaka et al 1981). Unreacted substrate was removed 
by repeated heptane extractions. Aliquots of the remaining aqueous layer were 
dissolved in scintillation fluid and counted. 
Acyl-CoA hydrolase." The assay was performed by incubating 20#g tissue in 
0.7ml of reaction mixture which contained 100mmol/L Tris-HC1 buffer (pH 7.4), 
1.25 mmol/L 5,5'-dithiobis-(2-nitrobenzoic acid), and 40/~mol/L acyl-CoA. The reac- 
tion of released CoASH with 5,5'-dithiobis-(2-nitrobenzoic acid) was monitored at 
412 nm by the rate analysis program of the Milton-Roy Diode Array Spectrophoto- 
meter (Berge and Farstad 1979). The acyl-CoA substrates were prepared as 0.5 mmol/L 
stock solutions in deionized water. Concentrations were confirmed by absorption at 
260 nm. 
CoA levels: Immediately after preparation, aliquots of fibroblast homogenate were 
extracted with ice-cold perchloric acid (6% v/v, final concentration) to separate 
soluble CoA moieties (CoASH and acetyl-CoA) from acid-insoluble long-chain and 
very long-chain acyl-CoA moieties. The acid-insoluble acyl-CoA pellets were washed, 
resuspended, hydrolysed, and neutralized as previously described (Moore et al 1982). 
The acid-soluble supernatant was neutralized and assayed directly for CoASH plus 
acetyl-CoA and, after treatment with N-ethylmaleimide, for direct analysis of acetyl- 
CoA (Allred and Guy 1969). The sensitive fluorimetric enzymatic cycling method of 
Veloso and Veech (1974) was used to assay neutralized fractions. Free CoASH 
content was estimated by subtracting acetyl-CoA content from total acid-soluble 
content. 
Total protein." Protein content was determined by the bicinchoninic acid assay 
(Smith et al 1985). 
Statistical significance." Statistical significance was assigned to data with p < 0.05 
as determined by the unpaired Student's t-test. 
RESULTS 
Fibroblasts from the patients and two infant controls were screened for their ability 
to oxidize lactate (Table 2). The infant control values represent the average of two 
controls each assayed in triplicate. Lactate oxidation was significantly decreased in 
NALD (76% inhibition) and RCDP (92% inhibition) compared to the infant control 
value of 1.9 + 0.1nmol/min per mg protein. These results suggested that the 
mitochondrial oxidation of pyruvate to CO2 by PDH was decreased in both of the 
patients' fibroblasts. Therefore, PDH activity was determined. PDH activity was 
significantly decreased in the NALD fibroblasts (34% inhibition) and the RCDP 
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Table 2 Lactate oxidation and pyruvate dehydrogenase activity in 
fibroblasts 
Lactate oxidation Pyruvate dehydrogenase 
Fibroblasts (nmol/min per nag protein) 
Control 1.9 ± 0.1 0.83 ± 0.02 
NALD 0.45 ± 0.015 a'b 0.55 ± 0.02 c 
RCDP 0.14 ± 0.003 a 0.44 ± 0.02 ° 
Results from a representative experiment were performed in triplicate. The 
results represent the mean + SEM. Similar results were obtained in at least 
3 additional experiments 
ap < 0.0005, compared with infant controls 
bp < 0.05, compared with RCDP 
cp < 0.01, compared with infant controls 
f ibroblas ts  (47% inhibi t ion)  as c o m p a r e d  with the infant  cont ro l  value of 
0.83 + 0.02 nmol /min  per  mg pro te in  (Table 2). The loca t ion  of P D H  on the inner  
mi tochondr i a l  m e m b r a n e  suggests that  the decrease in act ivi ty  observed in N A L D  
and R C D P  is a t t r ibu tab le  to mi tochondr i a l  dysfunction.  Since P D H  activi ty can be 
inhib i ted  in vitro by a var ie ty  of acy l -CoA species (Kiechle et al 1990b; M o o r e  et al 
1992), the acy l -CoA concen t ra t ion  in the f ibroblasts  was determined.  
The d is t r ibu t ions  of CoA species for infant  and  adul t  cont ro ls  and  pa t ien t  f ibroblasts  
are shown in Table  3. The infant cont ro ls  and  pat ients  were more  closely age-matched  
and their  results were compared .  F ib rob las t s  der ived from N A L D  had  ac id- insoluble  
acy l -CoA levels, inc luding acy l -CoA with chain length > Cs, a lmos t  3-fold higher  
than  those found in infant  cont ro l  f ibroblasts .  N A L D  f ibroblas ts  also demons t r a t ed  
a 2.2-fold increase in ace ty l -CoA content;  in contrast ,  the free C o A S H  in these 
f ibroblas ts  was only 6% of infant con t ro l  f ibroblasts .  To ta l  CoA (acid-insoluble acyl- 
CoA + acetyl  CoA + CoASH)  was e levated a lmos t  2-fold in N A L D .  The increased 
ester±fled C o A  and decreased free C o A S H  result  in d rama t i c  increases in bo th  acetyl-  
C o A / C o A S H  and  ac id- insoluble  a c y l - C o A / C o A S H  ra t ios  in N A L D  fibroblasts .  
Table 3 Fibroblast coenzyme A levels 
CoA species Infant controls Adult controls NALD RCDP 
(pmol/mg protein) 
Acid-insoluble acyl-CoA 45 ± 7 45 ± 11 129 ± 69 a 65 ± 15 b 
CoASH + acetyl-CoA 163 ± 37 154 ± 40 261 ± 64 194 ± 72 
Acetyl-CoA 115 ± 40 108 ± 24 258 ± 77" 137 ± 45 
CoASH 48 46 3 57 
Total CoA 208 199 390 259 
Ratios 
Acetyl-CoA/CoASH 2.40 2.35 86.0 2.40 
Acyl-CoA/CoASH 0.94 0.98 43.0 1.14 
Acid-insoluble acyl-CoA species represent those with chain length > C8:0 
Metabolite levels are expressed as pmol/mg protein, The data are means of 3 or more determinations ± SD 
ap < 0.01, bp <: 0.05, when compared with infant controls 
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RCDP fibroblasts had a total CoA content 25% greater than that observed for 
infant controls. The most significant change was a 44% increase in the long-chain 
acyl-CoA level. Despite the modest enhancement in the CoA content, the acetyl 
CoA/CoASH ratio was identical for both infant control and RCDP fibroblasts, but 
the long-chain acyl-CoA/CoASH was slightly elevated in RCDP fibroblasts. It should 
be noted that this study did not include quantitation of acid-soluble short- and 
medium-chain acyl-CoA species. Under most conditions these acyl-CoA species 
represent a very minor component of the total CoA pool (Moore et al 1988). 
Fibroblasts from both patients contained normal or enhanced levels of both 
mitochondrial (citrate synthase) and peroxisomal (catalase) marker enzymes (Table 
4). In addition, fibroblast homogenates were assayed for levels of enzymes involved in 
formation (acyl-CoA synthetase) and degradation (acyl-CoA hydrolase) ofintracellular 
acyl-CoA species (Table 4). Acyl-CoA synthetase was determined with a single 
substrate, palm±tic acid (16: 0), while three substrates, octanoyl-CoA (8:0), palmitoyl- 
CoA (16:0), and erucoyl-CoA (22:0), were employed in the acyl-CoA hydrolase 
assays. As seen in Table 4, the NALD fibroblasts had infant control levels of acyl- 
CoA synthetase as well as medium- and long-chain acyl-CoA hydrolase; however, 
the very long-chain acyl-CoA hydrolase activity was elevated 2.8-fold compared with 
the infant control. The RCDP fibroblasts exhibited a 36% decrease in palmitoyl- 
CoA synthetase (EC 6.2.1.3) activity and a 2.7-fold increase in the very long-chain 
acyl-CoA hydrolase activity. 
DISCUSSION 
Two children with peroxisomal disorders were found to have moderate lactic 
and pyruvic acidaemia, prompting this investigation of the interrelationship of 
mitochondrial and peroxisomal function. Lactic and pyruvic acidaemia are not 
described in patients with peroxisomal disorders, but previous findings suggest that 
these patients have altered mitochondrial function (Sarnat et al 1983; Wolff et al 
1986; Muller-Hocker et al 1984). Goldfischer et al (1973) first reported that patients 
with Zellweger syndrome lacked peroxisomes. Mitochondrial morphology was not 
Table 4 Fibroblast enzyme levels 
Activity Infant controls Adult controls NALD RCDP 
(nmol/min per mg protein) 
Catalase 6.85 +_ 1.40 7.63 + 1.80 
Citrate synthase 29.80 _+ 2.65 36.52 _+ 9.17 
Acyl-CoA synthetase 2.48 _+ 0.56 1.98 _+ 0.68 
Acyl-CoA hydrolase 
C8:0 18.93 _ 6.50 16.21 ± 7.22 
C16:o 22.59 ± 11.53 16.84 _+ 4.61 
C2z:0 1.88 _+ 1.41 
11.98 +_ 2.39 7.60 +__ 3.77 
27.10 ± 13.16 34.90 ± 2.40 
2.64 __ 0.71 1.58 _+ 0.50 b 
14.02 ± 7.55 13.36 _+ 6.77 
17.23 __ 9.74 16.25 _+ 7.21 
5.32 ± 2.71 a 5.02 ± 1.89 a 
Enzyme activities are expressed as nmol/min per mg protein. The data are means of 3 or more 
determinations _+ SD 
ap < 0.01, bp < 0.05, when compared with infant controls 
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described but cytochemical studies of intact brain mitochondria demonstrated reduced 
capability to oxidize succinate. 
Clinical and biochemical results suggest that our patients with peroxisomal 
disorders and acidosis have mitochondrial dysfunction. The conversion of radiolabelled 
lactate to radiolabelled CO2 appears to represent an excellent screening assay for 
potential metabolic errors that may lead to clinical lactic acidosis (Kerr 1991). 
Reduced PDH activity is the most common cause of congenital lactic acidosis and 
affected children present with a variable clinical picture (Robinson et al 1987). The 
NALD and RCDP patients both demonstrated decreased lactate oxidation and 
decreased PDH activity. 
Biochemical studies utilizing mitochondria in liver and muscle cells from patients 
with peroxisomal disorders have confirmed a defect in the electron-transport chain 
before the oxidative step involving cytochromes (Versmold et al 1977; Trijbels et al 
1983). Alterations in the biosynthesis of cell membranes (Poulos 1989; Naider and 
Moser 1990; Wanders et al 1990) and the accumulation of amphiphilic very long- 
chain acyl-CoA in peroxisomal disorders may lead to a disturbance in the structure 
of the inner mitochondrial membrane causing defects in the electron-transport chain 
(Trijbels 1983). The results of our studies utilizing fibroblasts show that the reactions 
localized to the inner mitochondrial membrane, i.e. the conversion of lactate to CO 2 
and PDH activity, are suppressed in NALD and RCDP. These results imply that 
the heterogeneous clinical presentation of patients with peroxisomopathies may be 
related to the degree of associated secondary mitochondrial dysfunction. 
Mitochondrial dysfunction may occur secondary to the intracellular accumulation 
of acyl-CoA species (Corkey et al 1988; Corkey and Deeney 1990). In the NALD 
and RCDP patients the acid-insoluble acyl-CoA concentration (long-chain and very 
long-chain species) is significantly increased compared to the infant and adult 
controls. Palmitoyl-CoA in the micromolar concentration range alters a variety of 
mitochondrial functions, like the activity of the pH-dependent anion-conducting 
channel (Halle-Smith et al 1988), steady-state transmembrane potentials (diLisa et al 
1989), PDH activity (Smith and Saggerson 1979; Lai et al 1989; Kiechle et al 1990a,b; 
Moore et al 1992), and other mitochondrial dehydrogenases (Lai and Cooper 1991). 
These experiments measuring PDH activity were performed in the absence of 
adenosine triphosphate, the substrate for the PDH kinase, excluding this enzyme as 
the mediator of the inhibition of mitochondrial PDH activity (Smith and Saggerson 
1979; Lai et al 1989; Lai and Cooper 1991). Other acyl-CoA species have been 
reported to inhibit (butyryl-CoA) or stimulate (malonyl-CoA, acetoacetyl-CoA, 
propionyl-CoA) PDH kinase activity by covalent acylation (Rahmatullah and Roche 
1985). The acetyl-CoA/CoASH is markedly increased in NALD compared to infant 
control (Table 3). This increased ratio is sufficient to activate PDH kinase in vitro, 
phosphorylate the enzyme complex and reduce activity (Denton et al 1978). This 
mechanism alone or in combination with mitochondrial damage induced by amphi- 
philic acyl-CoA may contribute to the decreased PDH activity observed in NALD. 
However, in RCDP this ratio is equivalent to the control, suggesting that the elevation 
in long-chain and very long-chain acyl-CoA species alone may be responsible for the 
inhibition of PDH activity. 
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To complement the above findings, we investigated the activity of a group of 
enzymes with the potential of altering mitochondrial and peroxisomal acyl-CoA 
pools. Homogenate acyl-CoA synthetase activity was assessed using palmitic acid as 
substrate (Table 4). Palmitoyl-CoA synthetase has a mitochondrial (21%), peroxisomal 
(16%), and microsomal (60%) distribution in liver (Bronfman et al 1984). There is 
evidence that separate long-chain and very long-chain acyl-CoA synthetases are 
found in peroxisomes (Lageweg et al 1991). Lazo et al (1988) propose that deficiency 
of the peroxisomal very long-chain acyl-CoA synthetase is responsible for the impaired 
oxidation of very long-chain fatty acids by fibroblasts from patients with X-linked 
adrenoleukodystrophy. Our NALD patient had normal levels of the palmitoyl-CoA 
synthetase in spite of dramatically elevated intracellular acyl-CoA levels. It is possible 
that the elevated acyl-CoA pool is due primarily to very long-chain acyl-CoAs that 
may alter the very long-chain acyl-CoA synthetase activity by feedback inhibition. 
The RCDP patient had significantly reduced levels of long-chain acyl-CoA synthetase, 
which may have prevented the dramatic acyl-CoA accumulation seen with the NALD 
patient. 
The activity of acyl-CoA hydrolase was elevated in both NALD and RCDP in the 
presence of very long-chain erucoyl-CoA substrate (Table 4). It is likely that this 
specific elevation was induced by accumulated very long-chain acyl-CoAs. Moore et 
al (1988) observed an increase in medium-chain acyl-CoA hydrolase activity subse- 
quent to medium-chain acyl-CoA accumulation due to valproic acid (2-propylpen- 
tanoic acid) feeding, and Kurooka et al (1971) correlated increased long-chain acyl- 
CoA hydrolase activity with the increased long-chain acyl-CoA content due to alloxan 
diabetes. As the long-chain acyl-CoA hydrolase activity (determined with palmitoyl- 
CoA) was not elevated in patients, it appears that there is a specific very long-chain 
acyl-CoA hydrolase enzyme. In light of the proposed role of acyl-CoA hydrolases as 
regulators of intracellular CoA pools (Berge and Aarsland 1985), it appears that both 
patients are hydrolysing very long-chain acyl-CoAs in order to maintain a normal 
CoASH concentration; the RCDP patient has achieved this metabolic goal, while 
the NALD patient, with a severely restricted CoASH pool, has been unsuccessful. 
Another indication of the metabolic response to the stress of accumulating acyl-CoAs 
is the expanded total CoA content found in the NALD fibroblasts. Increases in total 
CoA have also been correlated with enhanced acyl-CoA hydrolase activities (Moore 
et al 1988; Kurooka et al 1971). 
These two patients with peroxisomal disorders, NALD and RCDP, and moderate 
hyperlactataemia have been shown to exhibit decreased PDH activity which may be 
related to alterations in the pool of acyl-CoA species within the cell. These patients 
also exhibit alterations in the activity of enzymes involved in regulating the size of 
the acyl-CoA pool. These results suggest that the heterogeneity observed in the 
clinical presentation of the various peroxisomal disorders or within a specific 
peroxisomal disorder, as has been confirmed by complementation studies (Roscher 
et al 1989), may be related to the degree of mitochondrial dysfunction. 
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The First European Paediatric Congress, organized under the auspices 
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